In mid-May 2025, the FAMAR group acquired a sterile production site from MiP Pharma in Homburg (Saarland), Germany. In 2012, MiP commissioned a production site specializing in the packaging of sterile liquid and lyophilized pharmaceutical products for injection.

The site produces, in particular, MIP Pharma's antibiotic drugs aynat, with the active ingredients clindamycin and vancomycin.

The Homburg facility, which has recently undergone significant investment and modernization, will become an integral part of FAMAR's international manufacturing network. When the transaction closes, FAMAR will operate 7 facilities across Europe, enhancing its ability to serve its customers with flexible, high-quality, and scalable production solutions.

"The Homburg site offers world-class sterile infrastructure, newly installed QC and microbiology laboratories, and a skilled workforce," said Konstantinos Rengis, CEO of FAMAR Group. "This investment aligns with our strategy to grow in differentiated dosage forms and expand our capacity to support global customers with manufacturing services of the highest standards. We are proud to welcome the Homburg team to the FAMAR family and look forward to building a strong future together".

As part of the transaction, approximately 100 employees will transfer to FAMAR, ensuring continuity and knowledge retention. The site will be developed into a multi-customer CDMO platform under FAMAR ownership, fully aligned with the company's ambition to lead in complex and high-value pharmaceutical manufacturing.

In July 2024, ECM Partners and Metric Capital Partners signed an agreement to sell a majority stake in FAMAR to MidEuropa, a leading European private equity investor with over €6 billion in capital raised and managed over 25 years of history. However, the original shareholders maintained their investment in FAMAR, demonstrating their long-term commitment and confidence in FAMAR and its future potential.

Funds managed by ECM acquired FAMAR in March 2020 with a view of making the necessary investments to improve performance.

Since last year, Famar's new growth trajectory has erased the period of financial difficulties of 2019. In November 2019, Famar had to sell to Delpharm the activity of its three factories located in France, in Orléans, l'Aigle (Orne) and Saint-Rémy-sur-Avre (Eure-et-Loir) and the shares of the entities operating the sites of Bladel, in the Netherlands, and Pointe-Claire, in Quebec. These production units represented a turnover of 250 million euros and a total workforce of 1,300 employees.